Skip to main content
. 2014 Oct 6;111(42):E4429–E4438. doi: 10.1073/pnas.1407139111

Fig. 2.

Fig. 2.

Erbin mutation delays ErbB2-dependent tumorigenesis in vivo. (A) Kaplan–Meier survival plot. Log-rank (Mantel–Cox) test, P < 0.0001. Tumors were examined weekly in neu;erbin+/+ and neu;erbin−/− virgin littermates and sisters (n = 28 and 22, respectively). (B) Reduced tumor volumes in neu;erbin−/−, compared with neu;erbin+/+ littermates. Volumes were measured 5 wk after first detection of tumors for each mouse (n = 10 both groups; **P < 0.01). (C) Erbin mutation had no effect on tumorigenesis in MMTV-PyVT mice. Kaplan–Meier survival plot. Log-rank (Mantel–Cox) test, P > 0.05. Tumors were examined weekly in PyVT;erbin+/+ (n = 22) and PyVT;erbin−/− (n = 16) virgin littermates and sisters. (D) Erbin depletion had no effect on breast tumor growth in MMTV-PyVT mice. Tumors were weighed 3 wk after detection (n = 8; P > 0.05). (E) Hyperplasia in nontumor mammary glands of neu;erbin+/+ but not neu;erbin−/− littermates during diestrus phase at the same age. Tumor-free mammary glands were stained whole mount by hematoxylin. Arrows indicate branch buds of mammary ducts. (F) Quantitative analysis of data in E (n = 3; **P < 0.01). (G) Fewer Ki67-positive cells in nontransformed mammary glands of neu;erbin−/− mice. Tumor-free mammary gland sections were stained for E-cadherin (E-cad) and Ki67. (H) Quantitative analysis of results in G (n = 3; **P < 0.01).